Recently licensed: A start-up has partnered with us to accelerate the development of a therapy for steroid-resistant asthma.
This is a treatment for severe, steroid-resistant asthma. It enhances steroid activity by selectively inhibiting signalling pathways downstream of TGFẞ.
Up to 10 per cent of asthma patients are resistant to inhaled corticosteroids. New drugs to control corticosteroid-resistant severe asthma is a major priority.
Known compound PF670462 has achieved target validation. This compound enhances steroid activity, without evidence of autoimmune or cardiac toxicities.
Phone +61 3 8344 1919
Image: Animator - Andrew Lija/Composition - Alastair Stewart/Source - Boris Hinz 2015